Sep. 3 at 2:48 PM
If Trappsol Cyclo is so big a failure that data is best released in Japan, in the middle of the night (USA) we are going down hard as the company has indicated by every move since the merger that this (TRAPPSOL) is their main focus and concern.
June’s interim readout passed the safety test and will continue for another year with a 96-week data set ready by 1H of 2026. Why compromise that blinded data by releasing results now unless
$RFL can’t continue funding the study to its conclusion?
The problem is, nothing makes sense at
$RFL. Everything is shrouded in secrecy and littered with broken promises. Even the company (CYCLO) is now buried a layer deep in the organizational chart. And we’re left talking about conferences in Tokyo where we may or may not get data.
Oh, and btw, do we have and cancer trial data yet? Maybe that will prove to be a life saver.
